Abstract
Background: RA is a chronic and systemic inflammatory disease described by synovial inflammation and the progressive destruction of joint ligaments and bones. CXCR3 is a seven-transmembrane G-protein-coupled chemokine receptor that has been appeared to play a vital role in a variety of inflammatory and immunological responses. We aimed to evaluate the utility of serum CXCR3 levels in the diagnosis, monitor, and follow-up of RA patients. Methods: Sixty RA patients were divided into; 30 early RA patients with disease duration 0.001) and combined treatment (r=0.296, p=0.022). ROC curves were plotted for prediction of serum CXCR3 in RA patients. The best cut-off value of 4.026 ng/mL serum CXCR3 that indicate the presence of early RA disease with 71.7% sensitivity and 70% specificity (p=0.005). Conclusion: Serum CXCR3 is an imperative predictive biomarker for the diagnosis of RA and is an indicator of early RA disease and endorses the established RA disease.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
